Abstract

In both community and health care settings, Proteus mirabilis and the rest species of the Enterobacteriaceae family are prominent  pathogens for a variety of illnesses .In recent years, the incidence of isolation of Multidrug-Resistant bacteria (MDR) has grown, impacting hospitalized patients' prognosis and survival. meropenem is a β-lactam antibiotic  used intravenously to treat a broad range of bacterial illnesses; Meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax are only a few of them, while levofloxacin which is a quinolone antibiotic used to treat bacterial infections such as acute sinusitis, lung infection, Helicobacter pylori (in conjunction with other antibiotics), genitourinary infection and gut infections.
Evaluation of the effect of treatment with meropenem and levofloxacin on activity of ureases enzyme produced by meropenem /levofloxacin resistant Proteus mirabilis among UTIs patients. Samples were collected from 100 patients outpatients  aged between 25-80 years old males with a history of recurrent Urinary Tract Infection(UTI) caused by  Proteus mirabilis.   Among  them, 50 patients were take meropenem for ten days, and the rest of the patients received levofloxacin for the same period. General Urin Examination (GUE) was done before and after therapy to estimate the level of urease activity as a virulence factor for Proteus mirabilis. There was a significant reduction in urease activity when meropenem was used for treatment compared to Levofloxacin.Using meropenem is superior in a patient with resistant UTI caused by Proteus mirabilis upon levofloxacin.